By
Drug Target Review2024-03-20T16:00:27
The proof-of-concept study could lead to a cure for HIV that inactivates diverse strains across multiple cellular contexts.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-20T13:00:00Z
2026-11-18T11:12:00Z
2026-11-18T07:00:00Z
Contributor Dr Bryan McClellan and Dr William Matsui, By Drug Target Review
2026-11-18T07:00:00
Contributor Dr Bryan McClellan and Dr William Matsui, By Drug Target Review
2024-01-10T08:23:16
Sponsored by BellBrook Labs
2026-09-23T15:00:00
Sponsored by BioIVT
2026-06-02T15:00:00
Sponsored by Danaher
2024-02-08T11:07:39
Sponsored by Samplix ApS
2025-10-22T14:00:00
Sponsored by Wuxi Biologics
Site powered by Webvision Cloud